Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Joseph James

SHOCKING: Custom gene editing therapies for rare diseases could win faster approvals under fda draft plan not yet final - You Need To See This

The FDA on Oct. 27 released draft guidance that could speed approval of some gene-editing treatments built for a single patient's genetic mutation, a step rare disease families have pushed for since a Philadelphia infant received the first personalized CRISPR-based therapy last year.

The guidance outlines how one biologics license application, or BLA, could cover many patient-specific versions of a therapy. Under the plan, a new version that falls within preset limits could be added using laboratory data instead of a new clinical trial. The document is a draft open for public comment, and it does not approve any treatment.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.